Comparative Cardiovascular Efficacy of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists-A Network Meta-analysis

被引：0
|
作者：
Roddick, Alistair J.
Zheng, Sean
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-427-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] SGLT2 inhibitors vs. GLP-1 agonists: Comparative progression of renal disease
    Stevens, Lauren
    Bowe, Andy
    Schwab, Phil
    Tindal, Michael
    Bloomfield, Andrea
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 110 - 110
  • [42] Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
    Jimmy Gonzalez
    Benjamin A. Bates
    Soko Setoguchi
    Tobias Gerhard
    Chintan V. Dave
    Cardiovascular Diabetology, 22
  • [43] Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
    Gonzalez, Jimmy
    Bates, Benjamin
    Setoguchi, Soko
    Gerhard, Tobias
    Dave, Chintan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 5 - 5
  • [44] Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
    Gonzalez, Jimmy
    Bates, Benjamin A.
    Setoguchi, Soko
    Gerhard, Tobias
    Dave, Chintan V.
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [45] Cardiovascular risk and safety of SGLT2 inhibitors versus DPP-4 inhibitors: A nationwide comparative effectiveness research study
    Yang, Lanting
    Gabriel, Nico
    Guo, Serena Jingchuan
    Empey, Kerry M.
    Suh, Kangho
    Kane-Gill, Sandra L.
    Kirisci, Levent
    Hernandez, Inmaculada
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 145 - 145
  • [46] Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis
    Du, Yaping
    Bai, Lei
    Fan, Bingge
    Ding, Haixia
    Ding, Haiyan
    Hou, Lin
    Ma, Hongfang
    Xing, Na
    Wang, Fujun
    PRIMARY CARE DIABETES, 2022, 16 (01) : 156 - 161
  • [47] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [48] GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis
    Banerjee, Mainak
    Pal, Rimesh
    Maisnam, Indira
    Mukhopadhyay, Satinath
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2024, 18 (01)
  • [49] GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
    Karagiannis, Thomas
    Tsapas, Apostolos
    Athanasiadou, Eleni
    Avgerinos, Ioannis
    Liakos, Aris
    Matthews, David R.
    Bekiari, Eleni
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 174
  • [50] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    LANCET, 2021, 398 (10296): : 262 - 276
12345